HUE033458T2 - Orális készítmény kardiovaszkuláris betegségek kezelésére - Google Patents

Orális készítmény kardiovaszkuláris betegségek kezelésére Download PDF

Info

Publication number
HUE033458T2
HUE033458T2 HUE14728940A HUE14728940A HUE033458T2 HU E033458 T2 HUE033458 T2 HU E033458T2 HU E14728940 A HUE14728940 A HU E14728940A HU E14728940 A HUE14728940 A HU E14728940A HU E033458 T2 HUE033458 T2 HU E033458T2
Authority
HU
Hungary
Prior art keywords
coating
dosage
tablets
acid
salts
Prior art date
Application number
HUE14728940A
Other languages
English (en)
Inventor
Sanz Pablo Martin
Hurtado Javier Urbano
Original Assignee
Ferrer Int
Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii (Cnic)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033458(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Fundacion Centro Nac De Investigaciones Cardiovasculares Carlos Iii (Cnic) filed Critical Ferrer Int
Publication of HUE033458T2 publication Critical patent/HUE033458T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (3)

  1. ORÂiJS KÉSZÍTMÉNY KA&DÍÖV&S2KULÁR.ÍS SETECSSÈQEK KEZELÉSÉRE ^ény'P««tófc
    1. Orahvan adopk-osb gyPpyoxerekbe-i doxisfofw* ksedxxíaoxkniöno bseogsáo eargslSsnsn ésik&amp;pése ssrso a Mvétkeaékísi %dié»ass8 : ü:;} aoalihxa&amp;Pkisv, snint eien híkosnyag; ék HESG-CoA 'aduktâx sohnytoo svkm snissadik hatóanyag, ahoi ax ansii-oti HESö-CoA reduktâx inhibitor «s íMióíVíkkkialiA ês a á-;< sóik késni ke· !}! MvilfSlkMkfäv:dk »fiií (a> kodé vagy ióbb. egyszeres, k«i#p bevont abagstáa! egysig, asniky agy va-^y ^tsh. axt^n outran.’ ,<' η** «. 5««1 , no, vi »Vá-v a* η V ' ' n* o ,'*' e* ie '· o ,opN> \ í '' v ,1‘ psdmeíft w^y antaPié plrnedl! mentes, amely a bevonat öttsxetételének 0-S% tömegé·-« ko::«1* p-^nnyssége* soient. ¢.¾ apói a beyanat owmyiséne A-toi kk mgf<:tn£-ig terjed és nem monOO·'·”'· felSi-ahSíHkSS: pSOÍítt :01:050 pl py pgy Äfe: a§pasml4Ä-:itewti8^s|^M:^^i^i MZ. aíkspiss! PP%si iiásfeÉik Etrmlibm dsÂaièk:* la a vétken olöédtl plmer a sevrai «sites tömegén*;-* -KEk-át meghaladó Kooeyoy mennymáobeo és i:ak::p^fe8i|2ss^i<S0>>. mssbeo pidrö-tAdh pokvimt-sikohtit. po}sv»»|-aikdK>l «s esel kavfcf^»· KOA”' !ísváüpöl vmoktham |ôSp#:-â^iàpa^#M!Mfà ceopnítbói km«! mêëmmm.: |..:: A;: 1 igénypont ezennil alkalmasáéra ssöigáló yyögysxme.iieis Ässtems, aha! sx említet! öóx;^:>!?':'' kanosom maku .·:;.:. ... <5 ;$. As etöxó igénypontok bámmiyike sseentl ölkölmsxásfa ssokjáíó Qyogysxernsxeil äöx*?owt*. * ylïôldhaté pallnser ;a,:moxO*;···: tydrekMi! pikllnii-aikpHöki^,. ppiivipiiíiglkoApipst : on exek. keyefpkA^5'··’ ' opbppo!: k|n| :!ksk4|isgi%fâ;· . OX àl Aï xHÔzù ktlnvpontok tmnnsdvAe &amp;s«artit alkalmasé**·* sxoigâîo gyógysserésseti <3ôï:8*d^a cV" KÍ! 0::K! ac*kiy.aaiiC:k;tn·· dojveegyaége, ta; PS A-kat egyenïo vagy nagyobb etAnyiAeo PA-na! nagy«·«''·· eibovóeebben BEVom naovobh és mád ans iái ss asónyoníáíben bl'k-nál nagyobb n;or.nyli:·-'··· ° "........ “ .. .... ., y .. ,j.xv..ks®t®An tgítéPnastKál :.0:¾ npnt!!íiíkakp!ha:ykl 6Í osís·: disk? laloilye ; ··vagv' niopypSïSîs : pefft oieP, nnág Sio^y'·' '<' _ ...... ' ., ;,.;«;;;ί:·· '·> ρ«-·ν· n;nd n;; UîtA Gyógykxafklnyvy (US Pharasaaajxíiaj txenon 1. OpusC; káaxiiíáktK:·:·, k!/'-;b !·" ''' paíiarbetk 4:5 pH énék mosietp K;0 -pn; innbkotoxámmaí, SOOfb! iánngaiPan. . .·£! é'S I, »V P \-kJk' t V>S , ' NO* s ' 4 N Ν-,ΝΝ,Ν^ ^ * Ον N NX V a íb: «ösi'ipysajjök bevor:! tabietiák iosniáiéban vannak p;!*n §. Ax %ióx4 igénpoPtPk feármoiyie : sxenbil a!ka!max;lses vtkó pyôgyaxa-èavet! doxieinnas, 1 mi ’ ! vts < ín V I í '1 s tn ' n o> í(''t *( * ' N *i'n ' ladömánybsm ívem ?. As ski;:;) Inésvaoafck béÁóéiylkó óósíiób Aio-bassáis* νΑό ggógyasaréssal: óöAs.foín-s, alsói HbAACoA íóÁgkiás iiiiSiiisA ibénayiségs Is öfliiAéit óóAsioaASfcaa óóosaAysá<:aakb?k b Ali 4$ axpig |sí)Aóé l5ftöíSíA's'>4í;síi vm..
  2. 8. Aa síAkA sgéiyliiíok AAraAyiks; aaAílií aíkaknssás; a való: gyógyssésóssötl bsAaiobM, sk;öl HbKMIbA róolÁíáa iAniöiiif kaSó vagy tösfc AéA4A||ssi ÁsSíí4pbi«'s g-AAk mag.
    4. As síóaó igáoyponivh bámssiylk® Assisii afksksasAxss saaiyáió gyaavsMrrassa·; sóÁalómió., as:.ns% i-srUóaw fovsfcbá A8V v gx y íöt-b igys.SsbSA kaian adagaiba: ógyMsp. asaky sióba; ilan'Saóik hatéaaysokéal : .a sai'ia^-assnyo^-s· π reobssa·' i nbii léséi. ianai-yiSkka 10. Λ:·: elásó igény·:·«»; sslml AassAaká sMkióiö gyAgyissssobsaO óaxatoras·. óból a sAoosg^aggiotabain îiîbiigses· Ismbitsm egy ACEanMItaf, s ksvsikesAkbs? siló ssepsObói sevAkskAva: Tamipbl, kapsnell. t|ksil:gpb:; ósyfepm. sóliagók fóbiából %sbbpbj; laóoiabak ;ss«K>pí1i. pynydagrA sivaprô snapsi. splíSpik imsósiapríl és aAfeaspbk As :g:yôgysssÂssiié§: «ab eagy agy Mglóíggyis: íecepux Sjíékköíó: A kovalkeaökbbä álló ssopoéPói klyátessiVs; kosriáa. vélkAéiió, irbsAaitlso, ieiaxksarokk íöpgs.aA0a ApíéxgAáíyylsiPiarlílA: gölbssaéab, asóaban. ô|mâgarlâb; kiopP/aPan, keakariáe. E-k; ?? ó;> ZD-8/11 és ayógykskrékssillsg «ilogsólgsió sói
  3. 11. Ág silóaó Igébyjgjbl isgSóiol aikssmsygsfs sálé gyagyssiSpsssiil baAglAbba. ábél as arak*«'; ACk lobillspr íéklpól As gybgyssaaHsíaifeg öikkpPAski sói.
HUE14728940A 2013-06-06 2014-06-05 Orális készítmény kardiovaszkuláris betegségek kezelésére HUE033458T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
HUE033458T2 true HUE033458T2 (hu) 2017-12-28

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14728940A HUE033458T2 (hu) 2013-06-06 2014-06-05 Orális készítmény kardiovaszkuláris betegségek kezelésére

Country Status (42)

Country Link
US (1) US10617699B2 (hu)
EP (3) EP2810644A1 (hu)
JP (1) JP6151854B2 (hu)
KR (1) KR101839665B1 (hu)
CN (2) CN113143888A (hu)
AP (1) AP2015008882A0 (hu)
AR (1) AR096350A1 (hu)
AU (1) AU2014276883B2 (hu)
BR (1) BR112015030350B1 (hu)
CA (1) CA2912350C (hu)
CL (1) CL2015003561A1 (hu)
CR (1) CR20150635A (hu)
CU (1) CU24326B1 (hu)
CY (1) CY1118766T1 (hu)
DK (1) DK2986281T3 (hu)
DO (1) DOP2015000296A (hu)
EA (1) EA028969B1 (hu)
EC (1) ECSP15050273A (hu)
ES (1) ES2620078T3 (hu)
GE (1) GEP201706743B (hu)
HK (1) HK1204562A1 (hu)
HU (1) HUE033458T2 (hu)
IL (1) IL242569B (hu)
MA (1) MA38699B1 (hu)
MD (1) MD4475C1 (hu)
MX (1) MX347801B (hu)
MY (1) MY181272A (hu)
NI (1) NI201500171A (hu)
NZ (1) NZ714707A (hu)
PE (1) PE20160051A1 (hu)
PH (1) PH12015502706A1 (hu)
PL (1) PL2986281T3 (hu)
PT (1) PT2986281T (hu)
RS (1) RS55786B1 (hu)
SA (1) SA515370243B1 (hu)
SG (1) SG11201509353QA (hu)
SI (1) SI2986281T1 (hu)
TN (1) TN2015000501A1 (hu)
TW (1) TWI630928B (hu)
UA (1) UA113806C2 (hu)
WO (1) WO2014195421A1 (hu)
ZA (1) ZA201508452B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017021283A2 (pt) * 2015-04-16 2018-06-26 Novartis Ag comprimido de ribociclib
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
EP4299063B1 (en) 2022-06-30 2024-05-01 Ferrer Internacional, S.A. Oral capsules comprising atorvastatin tablets showing suitable dissolution profile and bioavailability

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
JP2000508659A (ja) 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
BRPI0108145B8 (pt) 2000-02-10 2021-05-25 Bpsi Holdings Inc composições de revestimento entérico acrílicas
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
CN1822820A (zh) * 2003-07-28 2006-08-23 雷迪实验室有限公司 心血管疾病的治疗和预防
JP4680061B2 (ja) 2003-08-20 2011-05-11 塩野義製薬株式会社 新規コーティング組成物
EP1689702B1 (en) 2003-11-26 2013-01-30 Novartis AG Organic compounds
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
CA2600674A1 (en) 2005-03-11 2006-09-14 Speedel Experimenta Ag Heterocyclic-substituted alkanamides useful as renin inhibitors
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
WO2009022821A2 (en) 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
KR20110007602A (ko) * 2008-03-28 2011-01-24 페레르 인터내쇼날 에스.에이. 심장혈관계 질병 예방용 캡슐
AU2010212580B2 (en) * 2009-02-11 2015-11-12 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
WO2011056126A1 (en) 2009-11-09 2011-05-12 Novadex Pharmaceuticals Ab Novel 1,3-oxazolidine compounds and their use as renin inhibitors
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
CU20150173A7 (es) 2016-06-29
EP3175849A1 (en) 2017-06-07
AP2015008882A0 (en) 2015-11-30
EP2810644A1 (en) 2014-12-10
CY1118766T1 (el) 2017-07-12
PE20160051A1 (es) 2016-01-25
US10617699B2 (en) 2020-04-14
SG11201509353QA (en) 2015-12-30
BR112015030350B1 (pt) 2022-11-29
TWI630928B (zh) 2018-08-01
CL2015003561A1 (es) 2016-06-10
TN2015000501A1 (en) 2017-04-06
MX347801B (es) 2017-05-15
EP2986281A1 (en) 2016-02-24
RS55786B1 (sr) 2017-07-31
PT2986281T (pt) 2017-03-29
EA028969B1 (ru) 2018-01-31
MD20160001A2 (ro) 2016-05-31
MD4475B1 (ro) 2017-04-30
NI201500171A (es) 2019-05-07
ES2620078T3 (es) 2017-06-27
EA201600012A1 (ru) 2016-07-29
AU2014276883A1 (en) 2015-11-26
WO2014195421A1 (en) 2014-12-11
KR20160014622A (ko) 2016-02-11
ECSP15050273A (es) 2017-07-31
MX2015015753A (es) 2016-08-03
GEP201706743B (en) 2017-09-25
ZA201508452B (en) 2017-02-22
MY181272A (en) 2020-12-21
AU2014276883B2 (en) 2017-04-20
EP2986281B1 (en) 2016-12-21
PH12015502706B1 (en) 2016-03-14
US20160106763A1 (en) 2016-04-21
CA2912350C (en) 2017-04-04
PH12015502706A1 (en) 2016-03-14
AR096350A1 (es) 2015-12-23
IL242569B (en) 2018-12-31
SI2986281T1 (sl) 2017-07-31
JP2016520135A (ja) 2016-07-11
BR112015030350A2 (pt) 2017-07-25
CR20150635A (es) 2016-06-10
CU24326B1 (es) 2018-03-13
SA515370243B1 (ar) 2016-09-19
JP6151854B2 (ja) 2017-06-21
CN113143888A (zh) 2021-07-23
PL2986281T3 (pl) 2017-06-30
MA38699B1 (fr) 2017-09-29
CA2912350A1 (en) 2014-12-11
CN104224804A (zh) 2014-12-24
TW201536357A (zh) 2015-10-01
HK1204562A1 (en) 2015-11-27
UA113806C2 (xx) 2017-03-10
KR101839665B1 (ko) 2018-03-16
DK2986281T3 (en) 2017-04-03
DOP2015000296A (es) 2016-12-30
MD4475C1 (ro) 2017-11-30
NZ714707A (en) 2019-04-26
MA38699A1 (fr) 2017-01-31

Similar Documents

Publication Publication Date Title
US10610488B2 (en) Sustained-release formulations of colchicine and methods of using same
RU2570752C2 (ru) Способы лечения сердечно-сосудистых нарушений
US20110117194A1 (en) Pharmaceutical formulation containing angiotensin-ii receptor blocker
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
CN101102755B (zh) 肾素抑制剂在制备预防或治疗舒张功能障碍或舒张性心力衰竭的药物中的用途
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2009010810A2 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
DK2986281T3 (en) ORAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASES
WO2018211479A1 (en) Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2008010008A2 (en) Cardiovascular combinations using rennin-angiotensin inhibitors
OA17601A (en) Oral formulation for the treatment of cardiovascular diseases.
KR20130074808A (ko) 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
CN101869710A (zh) 降压药物组合物
US20090061000A1 (en) Pharmaceutical formulation use 030
EP3998066A1 (en) Colchicine salicylate and uses thereof
KR20070058296A (ko) Ａｃｅ저해제와 스타틴류 약물의 복합제제 조성물 및 그의제조방법
MX2013015100A (es) Combinacion sinergica para el tratamiento de hipertension.